AU2020264143A1 - Crystal form S4 of the PLK4 inhibitor (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 H-imidazol-6- yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one fumarate - Google Patents
Crystal form S4 of the PLK4 inhibitor (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 H-imidazol-6- yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one fumarate Download PDFInfo
- Publication number
- AU2020264143A1 AU2020264143A1 AU2020264143A AU2020264143A AU2020264143A1 AU 2020264143 A1 AU2020264143 A1 AU 2020264143A1 AU 2020264143 A AU2020264143 A AU 2020264143A AU 2020264143 A AU2020264143 A AU 2020264143A AU 2020264143 A1 AU2020264143 A1 AU 2020264143A1
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- compound
- fumarate salt
- crystal form
- fumaric acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962837858P | 2019-04-24 | 2019-04-24 | |
| US62/837,858 | 2019-04-24 | ||
| PCT/CA2020/050535 WO2020215155A1 (en) | 2019-04-24 | 2020-04-23 | Crystal form s4 of the plk4 inhibitor (lr,2s)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 h-imidazol-6- yl)-5'-methoxyspiro[cyclopropane-l,3'-indolin]-2'-one fumarate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020264143A1 true AU2020264143A1 (en) | 2021-10-28 |
Family
ID=72940551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020264143A Pending AU2020264143A1 (en) | 2019-04-24 | 2020-04-23 | Crystal form S4 of the PLK4 inhibitor (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)- 1 H-imidazol-6- yl)-5'-methoxyspiro(cyclopropane-1,3'-indolin)-2'-one fumarate |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US12325700B2 (https=) |
| EP (1) | EP3959209A4 (https=) |
| JP (1) | JP7705351B2 (https=) |
| KR (1) | KR20220004102A (https=) |
| CN (1) | CN113966330B (https=) |
| AU (1) | AU2020264143A1 (https=) |
| BR (1) | BR112021021106A2 (https=) |
| CA (1) | CA3137191A1 (https=) |
| EA (1) | EA202192903A1 (https=) |
| IL (1) | IL287394A (https=) |
| MA (1) | MA55767A (https=) |
| MX (1) | MX2021012993A (https=) |
| SA (1) | SA521430647B1 (https=) |
| SG (1) | SG11202111003UA (https=) |
| TW (1) | TWI862582B (https=) |
| WO (1) | WO2020215155A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7717842B2 (ja) | 2021-05-11 | 2025-08-04 | オリック ファーマシューティカルズ，インク． | ポロ様キナーゼ４阻害剤 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7205328B2 (en) | 2002-10-21 | 2007-04-17 | Irm Llc | Oxindoles with anti-HIV activity |
| DE102005005395A1 (de) | 2005-02-03 | 2006-08-10 | Schering Aktiengesellschaft | Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel |
| GB0606234D0 (en) | 2006-03-29 | 2006-05-10 | Pliva Istrazivanje I Razvoj D | Pharmaceutically acceptable salts and polymorphic forms |
| EP2205241B1 (en) | 2007-09-25 | 2014-05-21 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
| EP2235004A4 (en) | 2007-12-21 | 2011-05-04 | Univ Health Network | INDAZOLYL, BENZIMIDAZOLYL, BENZOTRIAZOLYL-SUBSTITUTED INDOLUND DERIVATIVES AS A KINASE-HEMMER FOR CANCER TREATMENT |
| ES2465971T3 (es) | 2009-04-06 | 2014-06-09 | University Health Network | Inhibidores de quinasa y método para tratar cáncer con los mismos |
| US8586598B2 (en) | 2009-04-29 | 2013-11-19 | Nerviano Medical Sciences S.R.L. | CDK inhibitor salts |
| SI2556071T1 (sl) | 2010-04-06 | 2016-12-30 | University Health Network | Kinazni inhibitorji in njihova uporaba pri zdravljenju raka |
| ES2706066T3 (es) | 2010-07-02 | 2019-03-27 | Univ Health Network | Procedimiento dirigido a enfermedades mutantes con PTEN y composiciones para las mismas |
| WO2012048411A1 (en) | 2010-10-13 | 2012-04-19 | University Health Network | Plk-4 inhibitors and method of treating cancer with same |
| US9012464B2 (en) | 2010-11-25 | 2015-04-21 | Ratiopharm Gmbh | Salts and polymorphic forms of Afatinib |
| US20140051679A1 (en) | 2011-10-12 | 2014-02-20 | Univeristy Health Networks | Kinase inhibitors and method of treating cancer with same |
| WO2015054781A1 (en) | 2013-10-18 | 2015-04-23 | University Health Network | Treatment for pancreatic cancer |
| HUE043194T2 (hu) * | 2013-10-18 | 2019-08-28 | Univ Health Network | PLK-4 inhibitor sója és kristályformái |
-
2020
- 2020-04-23 CA CA3137191A patent/CA3137191A1/en active Pending
- 2020-04-23 JP JP2021562948A patent/JP7705351B2/ja active Active
- 2020-04-23 MA MA055767A patent/MA55767A/fr unknown
- 2020-04-23 SG SG11202111003UA patent/SG11202111003UA/en unknown
- 2020-04-23 TW TW109113591A patent/TWI862582B/zh active
- 2020-04-23 US US17/605,108 patent/US12325700B2/en active Active
- 2020-04-23 CN CN202080030678.8A patent/CN113966330B/zh active Active
- 2020-04-23 AU AU2020264143A patent/AU2020264143A1/en active Pending
- 2020-04-23 KR KR1020217037777A patent/KR20220004102A/ko not_active Ceased
- 2020-04-23 EP EP20795605.3A patent/EP3959209A4/en active Pending
- 2020-04-23 MX MX2021012993A patent/MX2021012993A/es unknown
- 2020-04-23 BR BR112021021106A patent/BR112021021106A2/pt unknown
- 2020-04-23 WO PCT/CA2020/050535 patent/WO2020215155A1/en not_active Ceased
- 2020-04-23 EA EA202192903A patent/EA202192903A1/ru unknown
-
2021
- 2021-10-19 IL IL287394A patent/IL287394A/en unknown
- 2021-10-20 SA SA521430647A patent/SA521430647B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021021106A2 (pt) | 2021-12-14 |
| WO2020215155A8 (en) | 2020-11-26 |
| TW202104216A (zh) | 2021-02-01 |
| JP7705351B2 (ja) | 2025-07-09 |
| KR20220004102A (ko) | 2022-01-11 |
| TWI862582B (zh) | 2024-11-21 |
| SA521430647B1 (ar) | 2024-01-27 |
| MX2021012993A (es) | 2021-12-10 |
| MA55767A (fr) | 2022-03-02 |
| IL287394A (en) | 2021-12-01 |
| US12325700B2 (en) | 2025-06-10 |
| WO2020215155A1 (en) | 2020-10-29 |
| EP3959209A4 (en) | 2022-12-28 |
| EA202192903A1 (ru) | 2022-02-09 |
| CA3137191A1 (en) | 2020-10-29 |
| EP3959209A1 (en) | 2022-03-02 |
| SG11202111003UA (en) | 2021-11-29 |
| US20220204494A1 (en) | 2022-06-30 |
| CN113966330A (zh) | 2022-01-21 |
| JP2022530028A (ja) | 2022-06-27 |
| CN113966330B (zh) | 2024-09-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11667627B2 (en) | Salt and crystal forms of PLK-4 inhibitor | |
| US20250171415A1 (en) | Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof | |
| AU2014336929A1 (en) | Salt and crystal forms of PLK-4 inhibitor | |
| US11878980B2 (en) | Solid forms of TTK inhibitor | |
| US12325700B2 (en) | Crystal form S4 of the PLK4 inhibitor (1R,2S)-(e)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1 h-imidazol-6-yl)-5′-methoxyspiro[cyclopropane-1,3′-indolin]-2′-one fumarate | |
| CN111606890A (zh) | 含丙烯酰基的核转运调节剂及其用途 | |
| EA044843B1 (ru) | Кристаллическая форма ингибитора plk4 | |
| CA3030230C (en) | Solid forms of ttk inhibitor | |
| HK40007702A (en) | Solid forms of ttk inhibitor | |
| HK40007702B (en) | Solid forms of ttk inhibitor | |
| HK1227404B (en) | Salt and crystal forms of plk-4 inhibitor | |
| HK1227404A1 (en) | Salt and crystal forms of plk-4 inhibitor |